European Federation of Pharmaceutical Industries and Associations

The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association and lobbying organisation, founded in 1978 and representing the pharmaceutical industry operating in Europe. Through its membership of 36 national associations and 39 leading pharmaceutical companies,[1] the EFPIA represents 1,900 European companies.[2]

EFPIA
European Federation of Pharmaceutical Industries and Associations
Formation1978
Founded atBrussels
PurposeTrade association
Location
  • Brussels, Belgium
Region served
Europe
Membership
37 national associations, 55 corporate members
Key people
Nathalie Moll (General Director)
Lars Fruergaard Jørgensen (President of the Board)
Staff (2023)
60
Websitewww.efpia.eu

EFPIA priorities

EFPIA priorities include the speeding up of regulatory approval and reimbursement processes for new medicines, creating a strong science base in Europe, joining forces with key stakeholders on political issues concerning health and addressing safety concerns. EFPIA also includes specialised groups like Vaccines Europe[3] who produce approximately 80% of vaccines used worldwide and European Biopharmaceutical Enterprises harness biotechnology to develop approximately one-fifth of new medicines.

Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is a public-private partnership designed by the European Commission and EFPIA. It is a pan-European collaboration that brings together large biopharmaceutical companies, small- and medium-sized enterprises (SMEs), patient organisations, academia, hospitals and public authorities. The initiative aims to accelerate the discovery and development of better medicines by removing bottlenecks in the drug development process. It focuses on creating better methods and tools that improve and enhance the drug development process, rather than on developing specific, new medicines.

Controversy

From 1991 to 1998 Emer Cooke worked for the EFPIA.[4] She became executive director of the European Medicines Agency (EMA), an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products, in November 2020.[5]

In a session of the Austrian Parliament member of parliament Gerald Hauser on 1 April 2021 publicly criticised a potential conflict of interest, by her allowing the controversial Oxford–AstraZeneca COVID-19 vaccine to be approved, while having worked for the very same industry in the past as a lobbyist of the EFPIA.[6][7]

See also

References
  1. "Board & Working Parties". www.efpia.eu. Retrieved 2023-04-05.
  2. "Who we are". www.efpia.eu. Retrieved 2022-05-31.
  3. "Vaccines Europe".
  4. "WHO | Emer Cooke". www.who.int. Archived from the original on 28 June 2020. Retrieved 15 January 2022.
  5. "Emer Cooke takes office as head of EMA | European Medicines Agency".
  6. "FPÖ – Hauser: EMA-Direktorin hat ihr ganzes Arbeitsleben mit Lobbying für die Pharmaindustrie verbracht | Freiheitlicher Parlamentsklub - FPÖ, 01.04.2021".
  7. Archived at Ghostarchive and the Wayback Machine: "Gerald Hauser zeigt Brisantes über die Impfstoffzulassung auf!". YouTube.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.